Eschenbach to Remain NCI Director While Running FDA

Drug Industry Daily
KEYWORDS FDA / People
A A

Andrew von Eschenbach will continue to be director of the National Cancer Institute, but will turn over day-to-day decisionmaking to a subordinate, while serving as interim FDA commissioner, agency spokespeople say.

To View This Article:

Login

Subscribe To Drug Industry Daily